207_Combined course Presentations

EGFR Mutation

120

100

extracellular ligand binding domain

80

transmembrane domain

60

40

specific mutations confer sensitivity of EGFR-TK activity to gefitinib/iressa in NSCLC patients ! s

delE746-A750 delL747-T751 delL747-P753 G719C

H1781 (WT)

H1666 (WT)

20

H441 (WT)

catalytic kinase domain

L858R L861Q

Cell viability (% of control) H3255 (L858R mutation)

0.001 0

0.01

0.1

1

10

Gefitinib concentration ( µ M)

Y1068

EGFR Mutations (gain of function) are associated with Increased Sensitivity to Gefitinib